Compile Data Set for Download or QSAR
Report error Found 595 Enz. Inhib. hit(s) with all data for entry = 2457
TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244736(US9428502, 346 | US10226449, cpd 346 | US202500179...)
Affinity DataEC50:  0.100nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244629(US9428502, 238 | US10226449, cpd 238 | US202500179...)
Affinity DataEC50:  1nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244568(US9428502, 177 | US10226449, cpd 177 | US202500179...)
Affinity DataEC50:  1nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244563(US9428502, 172 | US10226449, cpd 172 | US202500179...)
Affinity DataEC50:  1nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244632(US9428502, 241 | US10226449, cpd 241 | US202500179...)
Affinity DataEC50: <1nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244436(US9428502, 45 | US10226449, cpd 45)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244738(US9428502, 348 | US10226449, cpd 348 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244555(US9428502, 164 | US10226449, cpd 164 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244622(US9428502, 231 | US10226449, cpd 231 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244534(US9428502, 143 | US10226449, cpd 143 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244624(US9428502, 233 | US10226449, cpd 233 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244559(US9428502, 168 | US10226449, cpd 168 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244575(US9428502, 184 | US10226449, cpd 184 | US202500179...)
Affinity DataEC50:  2nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244677(US9428502, 287 | US10226449, cpd 287 | US202500179...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244535(US9428502, 144 | US10226449, cpd 144 | US202500179...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244438(US9428502, 47 | US10226449, cpd 47 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244609(US9428502, 295 | US9428502, 218 | US10226449, cpd ...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244681(US9428502, 291 | US10226449, cpd 291)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244423(US9428502, 32 | US10226449, cpd 32 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244422(US9428502, 31 | US10226449, cpd 31 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244440(US9428502, 49 | US10226449, cpd 49 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244690(US9428502, 300A | US10226449, cpd 300B)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244435(US9428502, 44 | US10226449, cpd 44 | US20250017938...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244398(US9428502, 7 | US10226449, cpd 7 | US20250017938, ...)
Affinity DataEC50:  3nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244437(US9428502, 46 | US10226449, cpd 46 | US20250017938...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244586(US9428502, 195 | US10226449, cpd 195 | US202500179...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244439(US9428502, 48 | US10226449, cpd 48 | US20250017938...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244585(US9428502, 194 | US10226449, cpd 194 | US202500179...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244434(US9428502, 43 | US10226449, cpd 43 | US20250017938...)
Affinity DataEC50:  4nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetFatty acid synthase(Human)
3-V Biosciences

US Patent
LigandPNGBDBM244437(US9428502, 46 | US10226449, cpd 46 | US20250017938...)
Affinity DataIC50: 5nMAssay Description:FASN activity of the SKBr3 cell extract was determined by measuring either NADPH oxidation or the amount of thiol-containing coenzyme A (CoA) release...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244595(US9428502, 204 | US10226449, cpd 204 | US202500179...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244418(US9428502, 27 | US10226449, cpd 27 | US20250017938...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244562(US9428502, 171 | US10226449, cpd 171 | US202500179...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244600(US9428502, 209 | US10226449, cpd 209 | US202500179...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244404(US9428502, 13 | US10226449, cpd 13 | US20250017938...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244737(US9428502, 347 | US10226449, cpd 347 | US202500179...)
Affinity DataEC50:  5nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244553(US9428502, 162 | US10226449, cpd 162 | US202500179...)
Affinity DataEC50:  6nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244569(US9428502, 178 | US10226449, cpd 178 | US202500179...)
Affinity DataEC50:  6nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetFatty acid synthase(Human)
3-V Biosciences

US Patent
LigandPNGBDBM244404(US9428502, 13 | US10226449, cpd 13 | US20250017938...)
Affinity DataIC50: 6nMAssay Description:FASN activity of the SKBr3 cell extract was determined by measuring either NADPH oxidation or the amount of thiol-containing coenzyme A (CoA) release...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244605(US9428502, 214 | US10226449, cpd 214 | US202500179...)
Affinity DataEC50:  6nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetFatty acid synthase(Human)
3-V Biosciences

US Patent
LigandPNGBDBM244398(US9428502, 7 | US10226449, cpd 7 | US20250017938, ...)
Affinity DataIC50: 6nMAssay Description:FASN activity of the SKBr3 cell extract was determined by measuring either NADPH oxidation or the amount of thiol-containing coenzyme A (CoA) release...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244735(US9428502, 345 | US10226449, cpd 345 | US202500179...)
Affinity DataEC50:  6nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244602(US9428502, 211 | US10226449, cpd 211 | US202500179...)
Affinity DataEC50:  6nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244566(US9428502, 175 | US10226449, cpd 175 | US202500179...)
Affinity DataEC50:  6nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244579(US9428502, 188 | US10226449, cpd 188)
Affinity DataEC50:  7nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244621(US9428502, 230 | US10226449, cpd 230 | US202500179...)
Affinity DataEC50:  7nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244571(US9428502, 180 | US10226449, cpd 180 | US202500179...)
Affinity DataEC50:  7nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244690(US9428502, 300A | US10226449, cpd 300B)
Affinity DataEC50:  7nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetFatty acid synthase(Human)
3-V Biosciences

US Patent
LigandPNGBDBM244438(US9428502, 47 | US10226449, cpd 47 | US20250017938...)
Affinity DataIC50: 7nMAssay Description:FASN activity of the SKBr3 cell extract was determined by measuring either NADPH oxidation or the amount of thiol-containing coenzyme A (CoA) release...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
3-V Biosciences

US Patent
LigandPNGBDBM244551(US9428502, 160 | US10226449, cpd 160 | US202500179...)
Affinity DataEC50:  7nMAssay Description:The antiviral activities of the compounds were assessed using the HCV1b replicon system. The replicon was constructed using the ET (luc-ubi-neo/ET) c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

Displayed 1 to 50 (of 595 total ) | Next | Last >>
Jump to: